Anesthetic Effect-Pipeline Review, H2 2015

Anesthetic Effect-Pipeline Review, H2 2015

  • Products Id :- GMDHC7236IDB
  • |
  • Pages: 97
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Anesthetic Effect-Pipeline Review, H2 2015


Global Markets Direct's, 'Anesthetic Effect-Pipeline Review, H2 2015', provides an overview of the Anesthetic Effect's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anesthetic Effect, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anesthetic Effect and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Anesthetic Effect

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Anesthetic Effect and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Anesthetic Effect products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Anesthetic Effect pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Anesthetic Effect

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Anesthetic Effect pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Anesthetic Effect Overview 9

Therapeutics Development 10

Pipeline Products for Anesthetic Effect-Overview 10

Pipeline Products for Anesthetic Effect-Comparative Analysis 11

Anesthetic Effect-Therapeutics under Development by Companies 12

Anesthetic Effect-Therapeutics under Investigation by Universities/Institutes 15

Anesthetic Effect-Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Anesthetic Effect-Products under Development by Companies 20

Anesthetic Effect-Products under Investigation by Universities/Institutes 22

Anesthetic Effect-Companies Involved in Therapeutics Development 23

Advicenne Pharma 23

Biolab Sanus Farmaceutica Ltda. 24

Drawbridge Pharmaceuticals Pty Ltd 25

Jiangsu Hengrui Medicine Co., Ltd. 26

Juniper Pharmaceuticals, Inc. 27

Laboratoires Thea S.A. 28

Lipicard Technologies Limited 29

Merck & Co., Inc. 30

NanoMedex Pharmaceuticals, Inc. 31

Paion AG 32

Phosphagenics Limited 33

Physica Pharma SAS 34

Proteus SA 35

Sphaera Pharma Pvt. Ltd. 36

Taiwan Liposome Company, Ltd. 37

The Medicines Company 38

Anesthetic Effect-Therapeutics Assessment 39

Assessment by Monotherapy Products 39

Assessment by Combination Products 40

Assessment by Target 41

Assessment by Mechanism of Action 43

Assessment by Route of Administration 45

Assessment by Molecule Type 47

Drug Profiles 48

(lidocaine hydrochloride + phenylephrine hydrochloride + tropicamide)-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

(tetracaine hydrochloride + oxymetazoline hydrochloride)-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ABP-700-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

ADV-6209-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

alphaxalone-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

bupivacaine hydrochloride-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

carboetomidate-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

Gabafol-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

HSK-3486-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

lidocaine hydrochloride ER-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

LT-1121-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

LT-1123-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

methoxycarbonyl carboetomidate-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

methoxycarbonyl etomidate-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

neosaxitoxin-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

PB-5109-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

PHY-301-Drug Profile 69

Product Description 69

Mechanism of Action 69

R&D Progress 69

propofol-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

propofol microemulsion-Drug Profile 71

Product Description 71

Mechanism of Action 71

R&D Progress 71

propofol-DM-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

remimazolam-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

remimazolam-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Small Molecules to Inhibit NMDA Receptor for Anaesthesia-Drug Profile 78

Product Description 78

Mechanism of Action 78

R&D Progress 78

sugammadex sodium-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

Anesthetic Effect-Recent Pipeline Updates 81

Anesthetic Effect-Dormant Projects 87

Anesthetic Effect-Discontinued Products 89

Anesthetic Effect-Product Development Milestones 90

Featured News & Press Releases 90

Oct 12, 2015: Remimazolam Posters at Anesthesiology 2015 90

Aug 11, 2015: Paion Starts EU Phase III Study With Remimazolam In The Indication General Anesthesia 91

Jun 15, 2015: Juniper Pharmaceuticals Announces First Patient Enrolled in Phase II Study of COL-1077 as an Acute-Use Anesthetic for Minimally-Invasive Gynecologic Procedures 92

Jun 08, 2015: PAION Announces Initiation Of Second U.S. Phase 3 Clinical Trial Of Remimazolam For Procedural Sedation During Bronchoscopy 92

Apr 28, 2015: FDA Declines To Approve Merck's Bridion 93

Mar 13, 2015: Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection 93

Feb 10, 2015: Drawbridge Pharmaceuticals granted Notice of Allowance for divisional patent in the United States 94

Nov 05, 2014: Paion's Partner Ono Decides Not To File For Regulatory Approval Of REMIMAZOLAM In Japan And Will Return Its REMIMAZOLAM Rights For Japan To Paion 94

Oct 14, 2014: Invitation To Conference Call Of Paion About The Project Status Of Remimazolam In Japan 95

Oct 10, 2014: Paion Expects Ono'S Remimazolm Decision On Filing In Japan In November 2014 95

Appendix 96

Methodology 96

Coverage 96

Secondary Research 96

Primary Research 96

Expert Panel Validation 96

Contact Us 96

Disclaimer 97

List of Tables

Number of Products under Development for Anesthetic Effect, H2 2015 10

Number of Products under Development for Anesthetic Effect-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Number of Products under Development by Companies, H2 2015 (Contd...1) 14

Number of Products under Investigation by Universities/Institutes, H2 2015 15

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Development, H2 2015 18

Comparative Analysis by Unknown Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd...1) 21

Products under Investigation by Universities/Institutes, H2 2015 22

Anesthetic Effect-Pipeline by Advicenne Pharma, H2 2015 23

Anesthetic Effect-Pipeline by Biolab Sanus Farmaceutica Ltda., H2 2015 24

Anesthetic Effect-Pipeline by Drawbridge Pharmaceuticals Pty Ltd, H2 2015 25

Anesthetic Effect-Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 26

Anesthetic Effect-Pipeline by Juniper Pharmaceuticals, Inc., H2 2015 27

Anesthetic Effect-Pipeline by Laboratoires Thea S.A., H2 2015 28

Anesthetic Effect-Pipeline by Lipicard Technologies Limited, H2 2015 29

Anesthetic Effect-Pipeline by Merck & Co., Inc., H2 2015 30

Anesthetic Effect-Pipeline by NanoMedex Pharmaceuticals, Inc., H2 2015 31

Anesthetic Effect-Pipeline by Paion AG, H2 2015 32

Anesthetic Effect-Pipeline by Phosphagenics Limited, H2 2015 33

Anesthetic Effect-Pipeline by Physica Pharma SAS, H2 2015 34

Anesthetic Effect-Pipeline by Proteus SA, H2 2015 35

Anesthetic Effect-Pipeline by Sphaera Pharma Pvt. Ltd., H2 2015 36

Anesthetic Effect-Pipeline by Taiwan Liposome Company, Ltd., H2 2015 37

Anesthetic Effect-Pipeline by The Medicines Company, H2 2015 38

Assessment by Monotherapy Products, H2 2015 39

Assessment by Combination Products, H2 2015 40

Number of Products by Stage and Target, H2 2015 42

Number of Products by Stage and Mechanism of Action, H2 2015 44

Number of Products by Stage and Route of Administration, H2 2015 46

Number of Products by Stage and Molecule Type, H2 2015 47

Anesthetic Effect Therapeutics-Recent Pipeline Updates, H2 2015 81

Anesthetic Effect-Dormant Projects, H2 2015 87

Anesthetic Effect-Dormant Projects (Contd...1), H2 2015 88

Anesthetic Effect-Discontinued Products, H2 2015 89

List of Figures

Number of Products under Development for Anesthetic Effect, H2 2015 10

Number of Products under Development for Anesthetic Effect-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Late Stage Development, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 17

Comparative Analysis by Early Stage Products, H2 2015 18

Assessment by Monotherapy Products, H2 2015 39

Number of Products by Targets, H2 2015 41

Number of Products by Stage and Targets, H2 2015 41

Number of Products by Mechanism of Actions, H2 2015 43

Number of Products by Stage and Mechanism of Actions, H2 2015 43

Number of Products by Routes of Administration, H2 2015 45

Number of Products by Stage and Routes of Administration, H2 2015 45

Number of Products by Stage and Molecule Types, H2 2015 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Advicenne Pharma

Biolab Sanus Farmaceutica Ltda.

Drawbridge Pharmaceuticals Pty Ltd

Jiangsu Hengrui Medicine Co., Ltd.

Juniper Pharmaceuticals, Inc.

Laboratoires Thea S.A.

Lipicard Technologies Limited

Merck & Co., Inc.

NanoMedex Pharmaceuticals, Inc.

Paion AG

Phosphagenics Limited

Physica Pharma SAS

Proteus SA

Sphaera Pharma Pvt. Ltd.

Taiwan Liposome Company, Ltd.

The Medicines Company

Anesthetic Effect Therapeutic Products under Development, Key Players in Anesthetic Effect Therapeutics, Anesthetic Effect Pipeline Overview, Anesthetic Effect Pipeline, Anesthetic Effect Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]